APA (7th ed.) Citation

Haas, S. L. d., Slamon, D. J., Martin, M., Press, M. F., Lewis, G. D., Lambertini, C., . . . Hurvitz, S. A. (2023, January). Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: An open-label, phase III study (KRISTINE). Breast Cancer Research.

Chicago Style (17th ed.) Citation

Haas, Sanne L. de, et al. "Tumor Biomarkers and Efficacy in Patients Treated with Trastuzumab Emtansine + pertuzumab Versus Standard of Care in HER2-positive Early Breast Cancer: An Open-label, Phase III Study (KRISTINE)." Breast Cancer Research Jan. 2023.

MLA (9th ed.) Citation

Haas, Sanne L. de, et al. "Tumor Biomarkers and Efficacy in Patients Treated with Trastuzumab Emtansine + pertuzumab Versus Standard of Care in HER2-positive Early Breast Cancer: An Open-label, Phase III Study (KRISTINE)." Breast Cancer Research, Jan. 2023.